Convatec Group PLC
ISIN: GB00BD3VFW73 | Ticker: CTEC | LEI: 213800LS272L4FIDOH92
Country: United Kingdom
Convatec is a global medical products and technologies company focused on solutions for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence care and infusion care.
Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care.
1978
Served areaWorldwide
Headcount10,000
Headquarters3 Forbury Place, 23 Forbury Road, RG1 3JH Reading – United Kingdom
| Line item in (usd) | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|
| Assets | N/A | 3,674,000,000.00 | 3,592,000,000.00 |
| Noncurrent Assets | N/A | 2,563,200,000.00 | 2,702,700,000.00 |
| Property Plant And Equipment | N/A | 366,700,000.00 | 400,400,000.00 |
| Other Noncurrent Receivables | N/A | 11,900,000.00 | 8,600,000.00 |
| Deferred Tax Assets | N/A | 28,900,000.00 | 26,600,000.00 |
| Noncurrent Restricted Cash And Cash Equivalents | N/A | 13,600,000.00 | 7,300,000.00 |
| Noncurrent Derivative Financial Assets | N/A | 0.00 | 200,000.00 |
| Current Assets | N/A | 1,110,800,000.00 | 889,300,000.00 |
| Inventories | N/A | 308,800,000.00 | 336,900,000.00 |
| Cash and cash equivalents | 565,400,000.00 | 463,400,000.00 | 143,800,000.00 |
| Current Restricted Cash And Cash Equivalents | N/A | 0.00 | 18,200,000.00 |
| Current Derivative Financial Assets | N/A | 15,100,000.00 | 26,400,000.00 |
| Equity And Liabilities | N/A | 3,674,000,000.00 | 3,592,000,000.00 |
| Equity | 1,670,700,000.00 | 1,694,800,000.00 | 1,609,700,000.00 |
| Issued Capital | N/A | 247,000,000.00 | 250,700,000.00 |
| Retained Earnings | N/A | -842,000,000.00 | -892,200,000.00 |
| Share Premium | N/A | 142,300,000.00 | 165,700,000.00 |
| Treasury Shares | N/A | 2,200,000.00 | 1,500,000.00 |
| Other Reserves | N/A | 126,500,000.00 | 165,200,000.00 |
| Merger Reserve | N/A | 2,098,900,000.00 | 2,098,900,000.00 |
| Liabilities | N/A | 1,979,200,000.00 | 1,982,300,000.00 |
| Noncurrent Liabilities | N/A | 1,410,000,000.00 | 1,449,200,000.00 |
| Noncurrent Provisions | N/A | 1,700,000.00 | 53,100,000.00 |
| Other Noncurrent Payables | N/A | 47,600,000.00 | 32,700,000.00 |
| Deferred Tax Liabilities | N/A | 87,200,000.00 | 83,200,000.00 |
| Noncurrent Derivative Financial Liabilities | N/A | 2,900,000.00 | 300,000.00 |
| Longterm Borrowings | N/A | 1,199,800,000.00 | 1,211,900,000.00 |
| Current Liabilities | N/A | 569,200,000.00 | 533,100,000.00 |
| Current Provisions | N/A | 5,000,000.00 | 100,200,000.00 |
| Trade And Other Current Payables | N/A | 342,500,000.00 | 346,600,000.00 |
| Current Tax Liabilities Current | N/A | 45,500,000.00 | 33,500,000.00 |
| Current Derivative Financial Liabilities | N/A | 11,700,000.00 | 32,500,000.00 |
| Line item in (usd) | 01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|
| Revenue | 2,038,300,000.00 | 2,072,500,000.00 |
| Profit Loss From Operating Activities | 203,600,000.00 | 207,300,000.00 |
| Finance Income | 800,000.00 | 5,500,000.00 |
| Finance Costs | 44,300,000.00 | 73,200,000.00 |
| Profit Loss Before Tax | 151,300,000.00 | 81,900,000.00 |
| Income Tax Expense Continuing Operations | 33,700,000.00 | 19,000,000.00 |
| Profit (loss) | 117,600,000.00 | 62,900,000.00 |
| Line item in (usd) | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|
| Profit (loss) | N/A | 117,600,000.00 | 62,900,000.00 |
| Adjustments For Income Tax Expense | N/A | 33,700,000.00 | 19,000,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -19,600,000.00 | -36,300,000.00 |
| Adjustments For Sharebased Payments | N/A | 16,400,000.00 | 16,700,000.00 |
| Cash Flows From Used In Operations | N/A | 400,600,000.00 | 384,500,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 36,300,000.00 | 55,400,000.00 |
| Interest Received Classified As Operating Activities | N/A | 800,000.00 | 5,500,000.00 |
| Cash Flows From Used In Operating Activities | N/A | 305,900,000.00 | 281,700,000.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 113,800,000.00 | 123,300,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -206,500,000.00 | -348,300,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 491,800,000.00 | 714,200,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 583,900,000.00 | 842,500,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 22,000,000.00 | 20,700,000.00 |
| Dividends Paid Classified As Financing Activities | N/A | 85,800,000.00 | 88,100,000.00 |
| Cash Flows From Used In Financing Activities | N/A | -199,900,000.00 | -237,100,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | -100,500,000.00 | -303,700,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -1,500,000.00 | -15,900,000.00 |
| Cash and cash equivalents | 565,400,000.00 | 463,400,000.00 | 143,800,000.00 |
Please note that some sums might not add up.
| Position Holder | Short Interest in Percent | Date |
|---|---|---|
| Kintbury Capital LLP | 0.52% | 18.10.23 |
| AKO Capital LLP | 1.44% | 09.08.23 |
| GLG Partners LP | 0.54% | 12.01.24 |
| Kintbury Capital LLP | 0.70% | 24.10.23 |
| AQR Capital Management, LLC | 0.50% | 12.09.23 |
| GLG Partners LP | 0.69% | 06.02.24 |
| AKO Capital LLP | 1.50% | 16.11.23 |
| GLG Partners LP | 0.66% | 25.01.24 |
| GLG Partners LP | 0.70% | 01.02.24 |
| Total | 7.25% |
GB00BD3VFW73
LEI213800LS272L4FIDOH92
SectorHealth Care Equipment & Services
IndustryHealth Care Equipment & Supplies
Sub-IndustryFTSE 100
Main Stock ExchangeKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.